The dysfunctional immune response in renal cell carcinoma correlates with changes in the metabolic landscape of ccRCC during disease progression.
Renal Cell carcinoma
T-cell exhaustion metabolic
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
28
11
2022
accepted:
05
10
2023
medline:
11
12
2023
pubmed:
9
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
Renal cell carcinoma is an immunogenic tumour with a prominent dysfunctional immune cell infiltrate, unable to control tumour growth. Although tyrosine kinase inhibitors and immunotherapy have improved the outlook for some patients, many individuals are non-responders or relapse despite treatment. The hostile metabolic environment in RCC affects the ability of T-cells to maintain their own metabolic programme constraining T-cell immunity in RCC. We investigated the phenotype, function and metabolic capability of RCC TILs correlating this with clinicopathological features of the tumour and metabolic environment at the different disease stages. Flow cytometric analysis of freshly isolated TILs showed the emergence of exhausted T-cells in advanced disease based on their PD-1
Identifiants
pubmed: 37940720
doi: 10.1007/s00262-023-03558-5
pii: 10.1007/s00262-023-03558-5
pmc: PMC10700462
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4221-4234Informations de copyright
© 2023. The Author(s).
Références
Immunity. 2016 Sep 20;45(3):701-703
pubmed: 27653602
Am J Transl Res. 2021 Oct 15;13(10):11048-11064
pubmed: 34786042
Cell Signal. 2019 Apr;56:1-14
pubmed: 30465826
Cell Rep. 2015 Jul 7;12(1):116-127
pubmed: 26119730
Aging (Albany NY). 2019 Sep 7;11(17):6999-7020
pubmed: 31493764
Int J Clin Exp Pathol. 2017 Nov 01;10(11):11114-11121
pubmed: 31966460
Pharmacol Res. 2021 Dec;174:105829
pubmed: 34411731
Br J Cancer. 2016 Aug 23;115(5):505-16
pubmed: 27490806
Cancer Res. 2018 Jan 1;78(1):115-128
pubmed: 29066514
Nat Cell Biol. 2014 Oct;16(10):992-1003, 1-15
pubmed: 25241037
Eur Urol Open Sci. 2022 Jan 22;37:14-26
pubmed: 35128482
Can Urol Assoc J. 2011 Aug;5(4):274-82
pubmed: 21801687
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Nature. 2014 Sep 11;513(7517):251-5
pubmed: 25043030
Cancer Res. 2017 Mar 1;77(5):1075-1082
pubmed: 27872087
FASEB J. 1994 Feb;8(2):174-81
pubmed: 8119488
Sci Rep. 2020 Apr 10;10(1):6220
pubmed: 32277125
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Oncoscience. 2014 Jan 03;1(2):117-31
pubmed: 25594006
J Exp Med. 2018 Apr 2;215(4):1091-1100
pubmed: 29511066
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630154
Mol Aspects Med. 2013 Apr-Jun;34(2-3):337-49
pubmed: 23506875
Cell Mol Immunol. 2021 Jul;18(7):1761-1771
pubmed: 32055005
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Semin Cancer Biol. 2013 Feb;23(1):18-25
pubmed: 22705278
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Immunology. 2017 Jan;150(1):35-44
pubmed: 27479920
J Clin Invest. 2019 Feb 1;129(2):442-451
pubmed: 30614813
Neuro Oncol. 2023 Apr 6;25(4):674-686
pubmed: 36054930
Sci Rep. 2021 Feb 22;11(1):4338
pubmed: 33619294
JCI Insight. 2017 Jun 15;2(12):
pubmed: 28614802
Brain Pathol. 2016 Jan;26(1):3-17
pubmed: 26269128
J Cell Physiol. 2005 Mar;202(3):654-62
pubmed: 15389572
Cancer Immunol Res. 2016 Sep 2;4(9):726-33
pubmed: 27491898
Oncotarget. 2017 Mar 7;8(10):16875-16886
pubmed: 28187435